Clinical trialPhase 2Terminated
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
- Outcome
- Stopped early. Results posted; no primary outcome with dataSlow accrual (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 1 February 2017
- Ended
- 7 September 2018
- Enrollment
- 2 participants
- Sites
- 1
- Primary outcomes
- Objective Radiographic Response Rate (ORR)
- Sponsor type
- Academic / other
- Results posted
- 11 December 2018
- Last update
- 27 November 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no primary outcome with dataAs posted on ClinicalTrials.gov ↗, registry record of 27 November 2020
- Primary outcome, no data
- Objective Radiographic Response Rate (ORR)The registry’s note: Due to low accrual, study was halted prematurely. No data, as no patients were analyzed.
- Participants
- FOLFIRINOX Treatment: 2 started, 2 completed
- Serious adverse events
- FOLFIRINOX Treatment: 0 of 2Participants with at least one serious adverse event, of those at risk, as posted
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas. This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high grade neuroendocrine carcinomas participants equally into two cohorts (first-line versus beyond first-line).
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Objective Radiographic Response Rate (ORR) [Up to 36 months].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression Free Survival (PFS) [Up to 36 months].